Trial: 202105166

A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Phase

I (Cancer Control)

Principal Investigator

Park, Haeseong

Disease Site

Breast; Cervix; Corpus Uteri; Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell; Other Female Genital; Ovary; Pancreas; Prostate

Learn more about this study at: clinicaltrials.gov